Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
2Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Context Therapeutics Inc. (CNTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
10Total relationships
2Distinct source URLs
8High confidence
0.846Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Context Therapeutics Inc. Suppliers
Ticker
Name
Confidence
Evidence
BIOATLA-INC
BIOATLA-INC
92%
The Company agreed to pay BioAtla $4.5 million within five business days of the Amendment Date and an additional $2.0 million by August 1, 2026.
LINK-ASSIGNMENT-FOR-THE-BENEFIT-OF-CREDITORS-LLC
LINK-ASSIGNMENT-FOR-THE-BENEFIT-OF-CREDITORS-LLC
90%
we purchased all of the assets of Link associated with CT-95, including patent rights, know-how, regulatory filings, and inventory of drug substance and drug product
LONZA-AG
LONZA-AG
90%
the Company has obtained active pharmaceutical ingredients and drug product for its product candidates from several third-party contract manufacturers, including Lonza AG
LONZA-SALES-AG
LONZA-SALES-AG
90%
the Company has obtained active pharmaceutical ingredients and drug product for its product candidates from several third-party contract manufacturers, including Lonza Sales AG
Context Therapeutics Inc. Customers
Ticker
Name
Confidence
Evidence
EMERGING-GROWTH-COMPANY
EMERGING-GROWTH-COMPANY
62%
me period in 2025. 26 Table of Contents Interest Income Interest income decreased by approximately $0.4 million for the three months ended March 31, 2026 as compared to the same period in 2025, prima…
LEERINK-PARTNERS-LLC
LEERINK-PARTNERS-LLC
62%
rketing, sales and distribution. Furthermore, we 23 Table of Contents have incurred and continue to incur significant costs associated with operating as a public company, including legal, accounting,…
Context Therapeutics Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CNTX-DEBT-8758
Warrants outstanding: 345530
90%
xbrl warrant detail from xbrl 2022-12-31.
CNTX-DEBT
Debt stack $282,424
90%
Market cache reports total debt of $282,424.
CNTX-DEBT-8759
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2022-12-31.
Context Therapeutics Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Context Therapeutics Inc..
Context Therapeutics Inc. Ownership
Holder
Name
Confidence
Evidence
CNTX-OWNER-MPM-BIOIMPACT-LLC
MPM BIOIMPACT LLC
90%
13F overlay lists MPM BIOIMPACT LLC as top holder; 61 tracked holders.
Context Therapeutics Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
